J&J's Gamma Brachytherapy System Effectively Reduces Restenosis - TCT
This article was originally published in The Gray Sheet
Executive Summary
Physicians treating in-stent restenosis with intravascular brachytherapy should avoid placing new stents at the time of radiation, Paul Teirstein, MD, Scripps Clinic, La Jolla, California cautioned in a Sept. 23 release announcing the results of the Johnson & Johnson GAMMA I trial.
You may also be interested in...
Implant Sciences System Could Address Gamma Radiation Safety Concerns
Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.
Implant Sciences System Could Address Gamma Radiation Safety Concerns
Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.
CDRH Guardedly Optimistic About Brachytherapy For In-Stent Restenosis
FDA Center for Devices and Radiological Health Director David Feigal praised the quality of evidence thus far demonstrating the safety and effectiveness of vascular brachytherapy in treating in-stent restenosis. At the same time, however, he cautioned that the agency would thoroughly review the data before making the therapy widely available.